LCAM
NVO

London & Capital Asset Management’s Novo Nordisk NVO Stock Holding History

London & Capital Asset Management’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-66,848
Closed -$4.61M – 98
2025
Q2 		$4.61M Sell
66,848
-54,736
-45% -$3.72M 0.35% 46
2025
Q1 		$8.44M Buy
121,584
+6,693
+6% +$553K 0.72% 35
2024
Q4 		$9.88M Buy
114,891
+11,740
+11% +$1.27M 0.84% 45
2024
Q3 		$12.3M Buy
103,151
+10,237
+11% +$1.37M 0.97% 40
2024
Q2 		$13.3M Buy
+92,914
New +$12.3M 1.12% 37

Other funds holding NVO

Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

London & Capital Asset Management's NVO Position: Q3 2025 in Review

London & Capital Asset Management sold out of Novo Nordisk (NVO) in Q3 2025, closing a stake of 66,848 shares — an estimated $4.61M sold.

London & Capital Asset Management first reported a position in NVO in Q2 2024 and held it in 5 quarters. The position peaked at $13.3M in Q2 2024. 1,396 funds tracked by Wall St. Rank hold NVO as of Q3 2025.

  • London & Capital Asset Management reported no remaining Novo Nordisk position as of Q3 2025 after selling out during the quarter.
  • London & Capital Asset Management sold 66,848 Novo Nordisk shares in Q3 2025, an estimated $4.61M.
  • London & Capital Asset Management first reported a position in Novo Nordisk in Q2 2024 and held it in 5 quarters.
  • London & Capital Asset Management's Novo Nordisk position peaked at $13.3M in Q2 2024.
  • 1,396 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2025.

Based on London & Capital Asset Management's 13F filing for Q3 2025, filed 12 Nov 2025.